Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263653 | 0.76 | PTGER3 (0.41) | PTGER3LMNAAKR1B1MEN1KMT2A | |
| SCHEMBL12862788 | 0.73 | LMNA (0.51) | PTGER3LMNAAKR1B1MEN1KMT2A | |
| SCHEMBL7945812 | 0.72 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL29688609 | 0.71 | AKR1B1 (0.44) | PTGER3LMNAAKR1B1TNFAKR1A1 | |
| SCHEMBL20135344 | 0.71 | AKR1B1 (0.44) | PTGER3LMNAAKR1B1TNFAKR1A1 | |
| SCHEMBL1173345 | 0.70 | AKR1B1 (0.50) | PTGER3LMNAAKR1B1AKR1A1 | |
| SCHEMBL1173343 | 0.70 | AKR1B1 (0.50) | PTGER3LMNAAKR1B1AKR1A1 | |
| SCHEMBL20135334 | 0.70 | LMNA (0.42) | PTGER3LMNAMEN1KMT2ATNF | |
| SCHEMBL29688911 | 0.70 | LMNA (0.42) | PTGER3LMNAMEN1KMT2ATNF | |
| SCHEMBL10736336 | 0.68 | TSHR (0.46) | PTGER3AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | PTGER3 886/4885LMNA 1280/4885AKR1B1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.